Research Topics
| H HoldaasSummaryAffiliation: Rikshospitalet University Hospital Country: Norway Publications
| Collaborators
|
Detail Information
Publications
A drug safety evaluation of everolimus in kidney transplantationHallvard Holdaas
Oslo University Hospital, Department of Transplant Medicine, Section of Nephrology, Rikshospitalet, Postbox 4950 Nydalen, N 0424 Oslo, Norway
Expert Opin Drug Saf 11:1013-22. 2012..Everolimus has the potential to become an important agent in de novo and maintenance immunotherapy in kidney transplant recipients...
Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot studySara Bremer
Department of Medical Biochemistry, Rikshospitalet University Hospital, Oslo, Norway
J Transl Med 7:64. 2009..The objective of this pilot study was to investigate the MPA PK and PD relation in combination with belatacept (2nd generation CTLA4-Ig) or cyclosporine (CsA)...
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trialHallvard Holdaas
Lancet 361:2024-31. 2003..We investigated the effects of fluvastatin on cardiac and renal endpoints in this population...- Acute renal allograft rejections, a role for statins?H Holdaas
Department of Medicine, National Hospital, Oslo, Norway
Minerva Urol Nefrol 55:111-9. 2003..Although in vitro studies have provided a theoretical basis for the use of statins as immunosuppressive agents, more recent clinical placebo controlled studies have failed to confirm the initial optimism of this effect of statins... - Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipientsH Holdaas
Department of Medicine, National Hospital, Sognsvannsveien 20, 0027 Oslo, Norway
Int J Clin Pharmacol Ther 44:163-71. 2006..To assess the pharmacokinetic interaction between cyclosporine and extended-release fluvastatin (fluvastatin XL), 80 mg for 7 days, in stable renal transplant recipients... - Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot studyH Holdaas
Section of Nephrology, Medical Department, The National Hospital, Oslo, Norway
Clin Transplant 22:366-71. 2008.... - Preventing cardiovascular outcome in patients with renal impairment: is there a role for lipid-lowering therapy?Hallvard Holdaas
Medical Department, National Hospital, University of Oslo, Oslo, Norway
Am J Cardiovasc Drugs 5:255-69. 2005..CVD in patients with CKD has been a neglected area of research... - Beneficial effect of early initiation of lipid-lowering therapy following renal transplantationHallvard Holdaas
Rikshospitalet, Sognsvannsvn 20, Oslo 0072, Norway
Nephrol Dial Transplant 20:974-80. 2005..The aim of the current analysis was to investigate the importance of time of initiation of therapy after transplantation, on the benefits of statin therapy... - The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trialsHallvard Holdaas
Medical Department, National Hospital, University of Oslo, 0027 Oslo, Norway
Int J Cardiol 117:64-74. 2007..Individuals with chronic kidney disease are at high risk for cardiovascular disease and have a high prevalence of hyperlipidemia. Lipid-lowering therapy may help patients with renal disease reduce their risk for cardiovascular events... - Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension studyH Holdaas
Rikshospitalet, Oslo, Norway
Am J Transplant 5:2929-36. 2005..The lipid-lowering and cardiovascular benefits of fluvastatin are comparable to those of statins in other patient groups, and support use of fluvastatin in RTR... - Rosuvastatin in diabetic hemodialysis patientsHallvard Holdaas
Department of Nephrology, Oslo University Hospital, Rikshospitalet, Oslo, Sognsvannsveien 22, 0072 Oslo, Norway
J Am Soc Nephrol 22:1335-41. 2011..68; 95% CI 0.51 to 0.90). In conclusion, among hemodialysis patients with diabetes mellitus, rosuvastatin might reduce the risk of fatal and nonfatal cardiac events... - Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month studyHallvard Holdaas
Medical Department, Rikshospitalet, University of Oslo, Oslo, Norway
Transplantation 92:410-8. 2011..Benefits of conversion from calcineurin inhibitor (CNI) to mammalian target of rapamycin inhibitor-based immunosuppression in long-term kidney transplant patients remain uncertain... - Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline dataH Holdaas
Department of Medicine, National Hospital, N 0027 Oslo, Norway
J Cardiovasc Risk 8:63-71. 2001..ALERT is the first large-scale prospective, randomized, double-blind study to address the prevention of cardiovascular mortality in renal transplant patients receiving an HMGCoA reductase inhibitor... - Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind studyK Midtvedt
Department of Nephrology, National Hospital, University of Oslo, Norway
Transplantation 72:107-11. 2001..The regression of left ventricular mass index is observed to a similar extent in patients treated with lisinopril or nifedipine... - Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trialI Holme
Oslo University Hospital, Ulleval, Centre of Preventive Medicine, Oslo, Norway
J Intern Med 267:567-75. 2010..73 m(-2)) and analysed relationships between lipoprotein components (LC) and major coronary events (MCE) and other cardiovascular (CV) events... - Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipientsA Asberg
Medical Department, The National Hospital, Oslo, Norway
Am J Transplant 1:382-6. 2001..0% (p < 0.0001), respectively. Bilateral pharmacokinetic interaction between atorvastatin and CsA resulted in sixfold higher plasma HMG-CoA reductase inhibitory activity, but only a moderate decrease in systemic exposure of CsA... - Efficacy of nifedipine or lisinopril in the treatment of hypertension after renal transplantation: a double-blind randomised comparative trialK Midtvedt
Medical Department, National Hospital, Rikshospitalet, 0027 Oslo, Norway
Clin Transplant 15:426-31. 2001..As monotherapy, both drugs show a "response rate" of 20-38%, depending on time interval after transplantation... - Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trialH Holdaas
Medical Department, National Hospital, 0027 Oslo, Norway
Kidney Int 60:1990-7. 2001..The present study is the first randomized, double-blind and adequately powered study to examine the effect of statins on acute rejection of renal allografts... - Prognostic model for total mortality in patients with haemodialysis from the Assessments of Survival and Cardiovascular Events (AURORA) studyI Holme
Oslo University Hospital, Ulleval, Oslo, Norway
J Intern Med 271:463-71. 2012..We used the database of the Assessment of Survival and Cardiovascular Events study to develop a prognostic model of mortality over 3-4 years... - Atorvastatin improves endothelial function in renal-transplant recipientsA Asberg
Laboratory for Renal Physiology, Section of Nephrology, Medical Department, The National Hospital, N-0027 Oslo, Norway
Nephrol Dial Transplant 16:1920-4. 2001..Plasma NO levels were increased during atorvastatin treatment, indicating a possible endothelial protective effect through an "endothelial-NO pathway"... - Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinoprilK Midtvedt
Department of Nephrology, The National Hospital, University of Oslo, Norway
Transplantation 72:1787-92. 2001..Patients receiving nifedipine but not lisinopril improved kidney transplant function over a period of 2 years... - Contrasting short-term effects of nifedipine on glomerular and tubular functions in glomerulonephritic patientsA Hartmann
Medical Department B, National Hospital, Oslo, Norway
J Am Soc Nephrol 5:1385-90. 1994..05), respectively. It was concluded that nifedipine treatment acutely represses proximal tubular function but is without significant effect on glomerular sieving and albuminuria in these patients... - The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac eventsJ Hjelmesaeth
Department of Medicine, Rikshospitalet University Hospital, Oslo, Norway
Kidney Int 69:588-95. 2006..20, 95% CI=0.58-2.49, P=0.621), were independent predictors of death in the multiple Cox regression model. Early-diagnosed PTDM is a predictor of MCEs, but not of all-cause mortality, the first 8 years after renal transplantation... - Ethics and safety of living kidney donationA Jakobsen
Department of Surgery, Rikshospitalet, 0027 Oslo, Norway
Transplant Proc 35:1177-8. 2003 - Quality of life in kidney donorsG Mjøen
Medical Department, Oslo University Hospital Rikshospitalet, Oslo, Norway
Am J Transplant 11:1315-9. 2011..They are fully reimbursed and offered life-long follow-up. All inhabitants are provided universal healthcare. This should be considered when extrapolating these results to other countries... - Report from the Norwegian National Hospitals Living Donor Registry: one-year data, January 1, 2002L Westlie
Norwegian National Hospital, University of Oslo, Oslo, Norway
Transplant Proc 35:777-8. 2003 - Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA studyBengt Fellstrom
Department of Medical Science, Renal Unit, University Hospital, Uppsala, Sweden
Kidney Blood Press Res 30:314-22. 2007..Cardiovascular disease (CVD) is the leading cause of death in patients with end-stage renal disease (ESRD)... - No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) studyBengt Fellstrom
Department of Medical Science, Renal Unit, University Hospital, Uppsala, Sweden
Clin Transplant 20:732-9. 2006..This study investigated the effect of fluvastatin treatment on renal function in renal transplant recipients enrolled in the Assessment of Lescol in Renal Transplantation (ALERT) trial... - The renal safety profile of fluvastatin: results of a pooled analysisHallvard Holdaas
The Medical Department, National Hospital, University of Oslo, Oslo, Norway
Ren Fail 28:487-92. 2006..This pooled analysis demonstrates that fluvastatin treatment across the approved daily dose range of 20 mg to 80 mg does not adversely affect creatinine or creatinine clearance over time in dyslipidemic patients... - Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipientsAnders Asberg
Laboratory for Renal Physiology, Medical Department, Rikshospitalet, Oslo, Norway
Transplantation 82:62-8. 2006..Calcineurin inhibitor (CNI)-free regimens posttransplantation have been claimed to conserve graft function in addition to reduce the risk factors for cardiovascular and malignant disease in renal transplant recipients... - Long-term clinical outcome of paediatric kidneys transplanted to adultsAksel Foss
Department of Surgery, Section of Transplant Surgery, Rikshospitalet University Hospital, N 0027 Oslo, Norway
Nephrol Dial Transplant 23:726-9. 2008..We have earlier shown an increase in the size and excellent graft function of paediatric kidneys transplanted to adults up to 1 year following transplantation. This study was performed to assess the long-term outcome of these transplants... - Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipientsJonathan B Singer
Clinical Pharmacogenetics, Novartis Institutes for BioMedical Research, Cambridge, MA, USA
J Lipid Res 48:2072-8. 2007..Polymorphisms in 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) previously reported to affect the efficacy of pravastatin did not show a similar effect on the reduction of LDL cholesterol by fluvastatin... - [Staging and measurement of renal function in chronic renal conditions]Anders Hartmann
Nyreseksjonen, Medisinsk avdeling, Rikshospitalet
Tidsskr Nor Laegeforen 126:1198-200. 2006..We address the importance and implications of these new definitions... - Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipientsPål Falck
Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, PO Box 1068 Blindern, 0316 Oslo, Norway
Nephrol Dial Transplant 23:1048-53. 2008..The calcimimetic drug cinacalcet offers a novel therapeutic option to treat post-transplant hypercalcemia and hyperparathyroidism; however, the interaction with calcineurin inhibitors and mycophenolate has not been evaluated... - Renal transplant dysfunction--importance quantified in comparison with traditional risk factors for cardiovascular disease and mortalityInga Soveri
Department of Medical Sciences, Uppsala University Hospital, entr 40, 75185, Uppsala, Sweden
Nephrol Dial Transplant 21:2282-9. 2006..The impact of renal dysfunction was compared with traditional risk factors for cardiovascular morbidity and mortality in 1052 placebo-treated patients of the ALERT trial... - The use of statins after solid organ transplantationHallvard Holdaas
Nephrol Dial Transplant 17:1537. 2002 - Risk for myopathy with statin therapy in high-risk patientsChristie M Ballantyne
Center for Cardiovascular Disease Prevention, Baylor College of Medicine, 6565 Fannin, Mail Station A601, Suite A656, Houston, TX 77030, USA
Arch Intern Med 163:553-64. 2003..Clinicians should be alert to the potential for drug-drug interactions to minimize the risk of myopathy during long-term statin therapy in patients at high risk for coronary heart disease... - Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantationAnders Asberg
Laboratory for Renal Physiology, Section of Nephrology, Medical Department, The National Hospital, Oslo, Norway
Clin Transplant 17:385-90. 2003..We therefore performed this study to assess the effect of fluvastatin on endothelial function in renal transplant recipients... - fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT StudyAlan G Jardine
Western Infirmary, Glasgow, Scotland, UK
Am J Transplant 4:988-95. 2004..The subgroups included patients at lower cardiovascular risk, who were younger, nondiabetic, nonsmokers and without pre-existing CVD. These data support the early introduction of statins following renal transplantation... - Fluvastatin and fluvastatin extended release: a clinical and safety profileAnders Asberg
Medical Department, National Hospital, Oslo, Norway
Expert Rev Cardiovasc Ther 2:641-52. 2004..The demonstration of the safe use of fluvastatin in a wide range of patients may be associated with the predominant acid form of the drug in vivo, as well as its predominant metabolism via the cytochrome P450 2C9 pathway... - Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trialBengt Fellstrom
Department of Medical Science, Renal Science, Renal Unit, University Hospital, Uppsala, Sweden
Transplantation 79:205-12. 2005.... - Atorvastatin does not affect the pharmacokinetics of cyclosporine in renal transplant recipientsMonica Hermann
Department of Pharmacology, School of Pharmacy, University of Oslo, PB 1068, Blindern, N 0316 Oslo, Norway
Eur J Clin Pharmacol 61:59-62. 2005..The aim of the present study was to evaluate the possible influence of atorvastatin on the pharmacokinetics of cyclosporine (INN ciclosporin) and its main metabolites, AM1 and AM9, in renal transplant recipients... - Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trialBengt Fellstrom
University Hospital, Uppsala, Sweden
Transplantation 79:1160-3. 2005..We evaluated the effects of baseline renal-transplant function on mortality and cardiovascular and renal endpoints in 1,052 placebo-treated patients of the Assessment of Lescol in Renal Transplantation trial... - Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) StudyAlan G Jardine
University of Glasgow, UK
Am J Kidney Dis 46:529-36. 2005..We analyzed the data in the placebo arm of Assessment of Lescol in Renal Transplantation (ALERT) to improve our understanding of the relationship between cardiovascular risk factors and outcomes in this unique population... - Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trialBengt Fellstrom
University Hospital, Uppsala, Sweden
Kidney Int 66:1549-55. 2004..The aim of the present study was to evaluate the effect of fluvastatin on long-term renal transplant function and development of chronic allograft nephropathy in the ALERT (Assessment of Lescol in Renal Transplantation) study... - Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantationAlberto Corsini
Department of Pharmacological Sciences, University of Milan, Milan, Italy
Ren Fail 27:259-73. 2005..This article characterizes the dyslipidemia observed in these clinical settings and reviews the clinical experience with fluvastatin... - The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled studyVincent L M Esnault
Pasteur Hospital, Universite de Nice Sofia Antipolis, Nice, France
Clin Ther 30:482-98. 2008.... - Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: lessons to be learnt from the assessment of Lescol in renal transplantation (ALERT) trialHallvard Holdaas
Am J Transplant 5:1574-5. 2005 - Gender-associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT studyCecilia Montgomery Oien
Faculty of Medicine, University of Oslo, Norway
Clin Transplant 20:374-82. 2006..Whether renal transplantation restores the gender-dependent cardiac protection and whether there is a difference in the impact of risk factors is not known... - Increased prevalence of gastrointestinal symptoms associated with impaired quality of life in renal transplant recipientsHenrik Ekberg
Department of Nephrology and Transplantation, Malmo University Hospital, Lund University, Malmo, Sweden
Transplantation 83:282-9. 2007..Immunosuppressive therapies have been associated with gastrointestinal (GI) side effects, which may impair health-related quality of life (HRQoL)... - The risk of living kidney donationAnders Hartmann
Nephrol Dial Transplant 18:871-3. 2003 - [How are living kidney donors doing?]Lars Westlie
Immunologisk institutt, Rikshospitalet 0027 Oslo
Tidsskr Nor Laegeforen 123:1060-2. 2003 - [Is current practice concerning living donors in kidney transplantations acceptable?]Lars Westlie
Immunologisk institutt, Rikshospitalet 0027 Oslo
Tidsskr Nor Laegeforen 123:1063-5. 2003 - Clinicians underestimate gastrointestinal symptoms and overestimate quality of life in renal transplant recipients: a multinational survey of nephrologistsHenrik Ekberg
Department of Nephrology and Transplantation, Malmo University Hospital, Lund University, Malmo, Sweden
Transplantation 84:1052-4. 2007..Improving patient-clinician communication could lead to more informed management, resulting in better HRQoL and increased graft survival... - [Type 2 diabetes and nephropathy--new studies, new treatment strategies?]Ingrid Os
Nyremedisinsk avdeling Ullevål universitetssykehus 0407 Oslo
Tidsskr Nor Laegeforen 122:918-20. 2002..It is important to lower the blood pressure to inhibit progression of renal failure and to prevent micro- and macrovascular disease in these patients. There is an ongoing discussion on what should be the drug of choice... - Statin therapy for prevention of coronary artery disease. The earlier the better or the longer the better?Hallvard Holdaas
Eur Heart J 29:425-6. 2008